Xilio Therapeutics, Inc. (XLO)

$1.01

+0.02

(+2.12%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $0.95
    $1.03
    $1.01
    downward going graph

    5.59%

    Downside

    Day's Volatility :7.43%

    Upside

    1.94%

    downward going graph
  • $0.49
    $2.94
    $1.01
    downward going graph

    51.49%

    Downside

    52 Weeks Volatility :83.33%

    Upside

    65.65%

    downward going graph

Returns

PeriodXilio Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-5.81%
5.3%
0.0%
6 Months
61.5%
6.3%
0.0%
1 Year
-63.91%
9.2%
0.0%
3 Years
-93.82%
13.1%
-19.9%

Highlights

Market Capitalization
35.8M
Book Value
$0.75
Earnings Per Share (EPS)
-2.57
Wall Street Target Price
5.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-46.46%
Return On Equity TTM
-128.37%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-56.8M
EBITDA
-70.3M
Diluted Eps TTM
-2.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.39
EPS Estimate Next Year
-0.94
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Xilio Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 444.55%

Current $1.01
Target $5.50

Technicals Summary

Sell

Neutral

Buy

Xilio Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.
6.25%
61.5%
-63.91%
-93.82%
-93.82%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.
NA
NA
NA
-1.39
-1.28
-0.46
NA
0.75
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.
Buy
$35.8M
-93.82%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Xilio Therapeutics, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 126.1%

Institutional Holdings

  • Bain Capital Life Sciences Investors, LLC

    7.60%
  • FMR Inc

    5.17%
  • RiverVest Venture Management LLC

    3.91%
  • Rock Springs Capital Management LP

    3.90%
  • Vanguard Group Inc

    2.45%
  • Balyasny Asset Management LLC

    0.92%

Company Information

xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com.

Organization
Xilio Therapeutics, Inc.
Employees
56
CEO
Dr. Rene Russo BCPS, Pharm.D.
Industry
Services

FAQs